NIMS launches next-generation sequencing for cancer care, first in Telangana government hospitals
In May 2026, Nizam’s Institute of Medical Sciences (NIMS) in Hyderabad began offering next-generation sequencing (NGS) tests for cancer patients. It is the first government-sector genetic cancer testing facility in Telangana.
Testing and treatment support
NGS tests identify genetic mutations in DNA and RNA to help doctors choose targeted or personalised cancer treatment. Eligible patients can receive the tests free under the Aarogyasri scheme. The testing may inform treatment decisions for stage-four lung, colorectal, ovarian and breast cancers, and for patients whose chemotherapy has failed.
Pilot testing and project
The service followed pilot testing of patient samples. Since 2024, more than 1,400 cancer patients had benefited from free molecular oncology diagnostic services, including patients with lung and breast cancer. NIMS established the facility under the Department of Health Research–Indian Council of Medical Research Advanced Molecular Oncology Diagnostic Services (DIAMOnDS) project.
Important Facts for Exams
- Parallel sequencing: NGS sequences spatially separated DNA templates simultaneously, whereas Sanger sequencing relies on electrophoretic separation of chain-termination products.
- Sequencing workflow: A typical NGS workflow amplifies library DNA, determines sequence through nucleotide addition, then reads spatially separated templates in parallel without physical separation.
- Emulsion PCR: In emulsion PCR, each water-oil droplet containing one bead acts as a microreactor, amplifying copies of the single DNA template attached to that bead.